Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Multiple Myeloma 30Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Graft vs Host Disease 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma 24Leukemia 24Hematologic Neoplasms 20Neoplasms 18Lymphoma, Mantle-Cell 18Sarcoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 17Tuberous Sclerosis 15Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Burkitt Lymphoma 14Waldenstrom Macroglobulinemia 13Lymphoma, B-Cell, Marginal Zone 13Recurrence 12Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Primary Myelofibrosis 11Melanoma 11Leukemia, Myelomonocytic, Chronic 11

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Cisplatin 3Immunoglobulin G 2Doxorubicin 2Disulfides 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1pegfilgrastim 1nintedanib 1linrodostat 1ixabepilone 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Metformin 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Sirolimus × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡